Prevenar® Summary of Prescribing Information | Prevenar 13®

This site is intended only for healthcare professionals resident in India

Log Out

Our medicines

Therapy areas

Explore Content

Explore content

Events

Materials

Videos

Let's connect

Pfizer medical information

About

Burden of Disease

Description of the Disease

Indian Epidemiology

Pneumococcal Disease and Influenza

Challenges

Risk Factors

Secondary Infections

Mechanism of Action

Prevention of Pneumococcal Disease

Need for Pneumococcal Vaccination

In Elderly

In India

Cost-effectiveness of PCV13

Indian Studies

Global Studies

Legacy of Prevenar

Manufacturing

CRM₁₉₇

Activation and Conjugation

Pneumococcal Disease and Influenza

Distribution

Videos

Safety

Conclusion

Conclusion

Dosing

Dosing

Adults ≥18 Years of Age

Adults ≥50 Years of Age

COVID Vaccination

Flu Vaccination

Efficacy

Prevenar 13^® Clinical Experience

Introduction

Clinical Trials

Efficacy of Prevenar 13^®

Methodology

Criteria

Results

Conclusion

Effectiveness of Prevenar 13^®

Methodology

Analysis

Results

Limitations

Learnings

Conclusion

Indian Clinical Trials

Limitations

Conclusion

Recommendations for Use

Recommendations for Use

ACIP 2019

NCCN 2020

RSSDI 2020

IMA Guidelines

IAOH Guidelines for Working Adults

Clinical Practice Guidelines 2019 (ICS/NCCP)

The Geriatric Society of India, 2015

Indian Society of Nephrology

FAQs

PCV13 in Pulmonology

Role

Complications

Clinical Data

Recommendations

PCV13 in Nephrology

PCV13 in Oncology

Clinical Data

PCV13 in Rheumatology

Complications

Data

Recommendations

Consensus

PCV13 in Diabetes

Data

Recommendations

PCV13 in HIV Infection

Burden

Pulmonary Infection

Data

Efficacy

Recommendations

PCV13 in Cardiology

Burden

Data

Recommendations

Resources

Resources

Summary of Prescribing Information

Downloadable Resources

Explore Events

Explore Videos

Explore Materials

Summary of Prescribing Information

PREVENAR 13® (Pneumococcal Polysaccharide Conjugate Vaccine [Adsorbed] I.P., 13-Valent) Summary of prescribing Information

Prevenar 13® - PFS, SDV,MDV- GDMS version 2, LPD no. LPDPRV062022 – India
(effective from 16-FEB- 2023)

PREVENAR 13®

Abbreviated Prescribing Information / Summary of Product Information

GENERIC NAME:

Pneumococcal Polysaccharide Conjugate Vaccine [Adsorbed] I.P., 13-Valent.

PRESENTATION:

Pre-filled syringe. 0.5 ml suspension for Injection in pre-filled syringe (Type I glass) with a plunger rod(polypropylene) and the syringe packaging includes hypodermic needle. Pack sizes of 1, 5, 10, 25 and 50. Not all presentation and pack sizes may be marketed.

INDICATION(s):

For active immunization for the prevention of Pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F (including sepsis, meningitis, bacteraemia, pneumonia) and acute otitis media in infants and children from 6 weeks to 5 years of age.
For active immunization for the prevention of Pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in children of 6 years to 17 years of age.
For active immunization for the prevention of Pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults of 18 years to 49 years of age.
For active immunization for the prevention of Pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in adults of 50 years and older age group.

DOSAGE AND ADMINISTRATION: (For intramuscular use only)

For infants, the immunization series of Prevenar 13® consists of 3 doses of 0.5ml each at 6 weeks, 10 weeks and 14 weeks of age, followed by a fourth dose of 0.5 ml at 12-15 months of age. The customary age for the first dose is 2 months of age, but it can be given as young as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at least 2 months after the third dose.

For children 6 years to 17 years of age, 1 dose of 0.5 mL Prevenar 13®.
Adults ≥18 years of age, One single dose.
For adults 50 years of age and older, Prevenar13 is to be administered as a single dose, including for those previously vaccinated with a pneumococcal polysaccharide vaccine.

The vaccine should be given by intramuscular injection. The preferred sites are the anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in children and adults.

Prevenar 13 has been shown to be safe and immunogenic in the geriatric population.
Individuals who have underlying conditions predisposing them to invasive pneumococcal disease (such as sickle cell disease or HIV infection) including those previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine may receive at least one dose of Prevenar 13.

In individuals with a haematopoietic stem cell transplant (HSCT), the recommended immunisation series consists of four doses of Prevenar 13, each of 0.5 ml. The primary series consists of three doses, with the first dose given at 3 to 6 months after HSCT and with an interval of at least 1 month between doses. A fourth (booster) dose is recommended 6 months after the third dose

CONTRAINDICATIONS: Hypersensitivity to the active substances, to any of the excipients listed in section 2 Qualitative and Quantitative Composition, or to diphtheria toxoid. As with other vaccines, the administration of Prevenar 13 should be postponed in subjects suffering from acute, severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

WARNING AND PRECAUTIONS:

Prevenar 13® must not be administered intravascularly.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
This vaccine should not be given as an intramuscular injection to individuals with thrombocytopaenia or any coagulation disorder that would contraindicate intramuscular injection, but may be given subcutaneously if the potential benefit clearly outweighs the risks.
Prevenar 13 will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease, pneumonia, or otitis media. As with any vaccine, Prevenar 13 may not protect all individuals receiving the vaccine from pneumococcal disease.
Individuals with impaired immune responsiveness, whether due to the use of immuno-suppressive therapy, a genetic defect, human immunodeficiency virus (HIV) infection, or other causes, may have reduced antibody response to active immunisation.
Safety and immunogenicity data are available for a limited number of individuals with sickle cell disease, HIV infection, or with an haematopoietic stem cell transplant Safety and immunogenicity data for Prevenar 13 are not available for individuals in other specific immuno-compromised groups (e.g., malignancy or nephrotic
syndrome) and vaccination should be considered on an individual basis.
Infants and children aged 6 weeks to 5 years
The use of pneumococcal conjugate vaccine does not replace the use of 23-valent pneumococcal polysaccharide vaccines in children ≥2 years of age with conditions (such as sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immuno-compromised) placing them at higher risk for invasive disease due to Streptococcus pneumoniae. Whenever recommended, children at risk who are ≥24
months of age and already primed with Prevenar 13 should receive 23-valent pneumococcal polysaccharide vaccine.
The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born ≤28 weeks of gestation), and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.

For vaccine serotypes, protection against otitis media is expected to be lower than protection against invasive disease.
Antipyretic treatment should be initiated according to local treatment guidelines for children with seizure disorders or with a prior history of febrile seizures and for all children receiving Prevenar13 simultaneously with vaccines containing whole cell pertussis.

DRUG INTERACTIONS:

Infants and children aged 6 weeks to 5 years: Prevenar 13 can be given with any of the following vaccine antigens, either as monovalent or combination vaccines: diphtheria, tetanus, acellular or whole-cell pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, meningococcal serogroup C, measles, mumps, rubella, varicella and rotavirus vaccine.
Prevenar 13 can also be given concomitantly between 12-23 months with the tetanus toxoid conjugated meningococcal polysaccharide serogroups A, C, W and Y vaccine to children who have been adequately primed with Prevenar 13
Adults aged 50 years and older: Prevenar 13 can be administered concomitantly with trivalent inactivated influenza vaccine (TIV). The immune responses to all four QIV strains were noninferior when Prevenar 13 was given concomitantly with QIV compared to when QIV was given alone.
Different injectable vaccines should always be given at different vaccination sites.

OVERDOSE:

Overdose with Prevenar 13 is unlikely due to its presentations as a pre-filled syringe. However, in infants and children there have been reports of overdose with Prevenar 13 defined as subsequent doses administered closer than recommended to the previous dose. In general, adverse events reported with overdose are consistent with those that have been reported with doses given in the recommended paediatric schedules of Prevenar 13

ADVERSE REACTION:

Infants and children aged 6 weeks to 5 years: Pyrexia; irritability; any vaccination-site erythema, induration/swelling or pain/tenderness; vaccination-site movement impairment (due to pain), somnolence; poor quality sleep, Vaccination-site erythema or induration/swelling 2.5 cm–7.0 cm
Children and adolescents 6 to 17 years of age: Irritability; any vaccination-site erythema; induration/swelling or pain/tenderness; somnolence; poor quality sleep; vaccination-site tenderness (including impaired movement), Pyrexia
Adults ≥18 years and elderly: Chills; fatigue; vaccination-site erythema; vaccination-site induration/swelling; vaccination-site pain/tenderness (severe vaccination-site pain/tenderness very common in adults aged 18 to 39 years); limitation of arm movement (severe limitation of arm movements very common in adults aged 18 to 39 years). Pyrexia (very common in adults aged 18 to 29 years), Arthralgia; myalgia

PHARMACEUTICAL PRECAUTIONS:

Store refrigerated at 2°C to 8°C. Do not freeze. Discard if the vaccine has been frozen. Store in original package. Keep out of reach of children.

During storage, a white deposit and clear supernatant can be observed. This does not constitute a sign of deterioration.

The vaccine is a suspension containing an adjuvant. The vaccine should be shaken well to obtain a homogeneous white suspension and should be inspected visually for any particulate matter and/or variation of physical aspect prior to administration. Do not use if the content appears otherwise. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Shelf life: 36 months.

Reference:

PREVENAR 13® – PNEUMOCOCCAL CONJUGATE VACCINE 13-VALENT (PFS, MDV,SDV) – GDMS version 4.0 (LPDPRV062022)

Full prescribing information available on request.

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
^®Trademark Proprietor – Wyeth LLC, USA. Licensed User – Pfizer Limited, India.

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

PP-PRV-IND-0661 July 2023

Resources

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more

Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more

Efficacy

Efficacy proven by the CAPiTA study

Learn more

Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.

Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.

PP-PRV-IND-0661

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Button

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein

You are now leaving PfizerPro website

You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-DOL-IND-0251 18 JAN 2023